<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiovascular</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиоваскулярная терапия и профилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Cardiovascular Therapy and Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1728-8800</issn><issn pub-type="epub">2619-0125</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1728-8800-2020-2729</article-id><article-id custom-type="elpub" pub-id-type="custom">cardiovascular-2729</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>БИОБАНКИРОВАНИЕ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>BIOBANKING</subject></subj-group></article-categories><title-group><article-title>Биобанк COVID-19: особенности цитокинового профиля</article-title><trans-title-group xml:lang="en"><trans-title>COVID-19 biobank: features of the cytokine profile</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5100-5229</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сушенцева</surname><given-names>Н. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Sushentseva</surname><given-names>N. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Наталья Николаевна Сушенцева — биолог </p><p>SPIN: 5187-2286</p><p>Сестрорецк</p></bio><bio xml:lang="en"/><email xlink:type="simple">navicula@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1778-0165</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Попов</surname><given-names>О. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Popov</surname><given-names>O. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Олег Сергеевич Попов — специалист </p><p>SPIN: 5220-9174</p><p>Сестрорецк</p></bio><bio xml:lang="en"/><email xlink:type="simple">ospopov@outlook.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3853-4185</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Апалько</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Apalko</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Светлана Вячеславовна Апалько — биолог, зав. лабораторией</p><p>Сестрорецк</p></bio><bio xml:lang="en"/><email xlink:type="simple">svetlana.apalko@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5642-621X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Анисенкова</surname><given-names>А. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Anisenkova</surname><given-names>A. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Анна Юрьевна Анисенкова. — зав. отделением терапии, врач-терапевт</p><p>Сестрорецк</p></bio><bio xml:lang="en"/><email xlink:type="simple">anna_anisenkova@list.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7831-6126</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Азаренко</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Azarenko</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сергей Владимирович Азаренко — врач-терапевт фармаколог</p><p> </p></bio><bio xml:lang="en"/><email xlink:type="simple">azsergey@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2339-1633</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сманцерев</surname><given-names>К. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Smantserev</surname><given-names>K. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Константин Вячеславович Сманцерев — врач анестезиолог-реаниматолог</p><p>Сестрорецк</p></bio><bio xml:lang="en"/><email xlink:type="simple">kvsmantserev@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2943-9004</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хоботников</surname><given-names>Д. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Khobotnikov</surname><given-names>D. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Дмитрий Николаевич Хоботников — врач анестезиолог-реаниматолог</p><p>Сестрорецк</p></bio><bio xml:lang="en"/><email xlink:type="simple">hobotnikovdn@gb40.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1709-669X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гладышева</surname><given-names>Т. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Gladysheva</surname><given-names>T. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Татьяна Вадимовна Гладышева — врач анестезиолог-реаниматолог</p><p>Сестрорецк</p></bio><bio xml:lang="en"/><email xlink:type="simple">gladishevatv@gb40.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2606-7057</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Минина</surname><given-names>Е. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Minina</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Евдокия Михайловна Минина — врач-рентгенолог</p><p>Сестрорецк</p></bio><bio xml:lang="en"/><email xlink:type="simple">mininaem@gb40.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8665-742X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Стрелюхона</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Strelyukhina</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Светлана Владимировна Стрелюхона — врач функциональной диагностики</p><p>Сестрорецк</p></bio><bio xml:lang="en"/><email xlink:type="simple">strelukhinasv@gb40.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5441-2911</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Уразов</surname><given-names>С. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Urazov</surname><given-names>S. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Станислав Петрович Уразов — врач-кардиолог</p><p>Сестрорецк</p></bio><bio xml:lang="en"/><email xlink:type="simple">urasta@list.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4247-965X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Павлович</surname><given-names>Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Pavlovich</surname><given-names>D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Драгана Павлович — специалист</p><p>Сестрорецк</p></bio><bio xml:lang="en"/><email xlink:type="simple">dragana.pavlovich@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5796-2444</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Фридман</surname><given-names>С. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Fridman</surname><given-names>S. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Светлана Романовна Фридман — врач клинический фармаколог</p><p>Сестрорецк</p></bio><bio xml:lang="en"/><email xlink:type="simple">fridmansr@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5047-2792</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Щербак</surname><given-names>С. Г</given-names></name><name name-style="western" xml:lang="en"><surname>Shcherbak</surname><given-names>S. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сергей Григорьевич Щербак — главный врач больницы</p><p>SPIN: 1537-9822</p><p>Сестрорецк; Санкт-Петербург</p></bio><bio xml:lang="en"/><email xlink:type="simple">sgsherbak@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>СПб ГБУЗ «Городская больница №40 Курортного района»</institution></aff><aff xml:lang="en"><institution>City Hospital № 40</institution></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>СПб ГБУЗ «Городская больница №40 Курортного района»; &#13;
Санкт-Петербургский государственный университет</institution></aff><aff xml:lang="en"><institution>City Hospital № 40; 2Saint Petersburg State University</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>24</day><month>12</month><year>2020</year></pub-date><volume>19</volume><issue>6</issue><fpage>2729</fpage><lpage>2729</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Сушенцева Н.Н., Попов О.С., Апалько С.В., Анисенкова А.Ю., Азаренко С.В., Сманцерев К.В., Хоботников Д.Н., Гладышева Т.В., Минина Е.М., Стрелюхона С.В., Уразов С.П., Павлович Д., Фридман С.Р., Щербак С.Г., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Сушенцева Н.Н., Попов О.С., Апалько С.В., Анисенкова А.Ю., Азаренко С.В., Сманцерев К.В., Хоботников Д.Н., Гладышева Т.В., Минина Е.М., Стрелюхона С.В., Уразов С.П., Павлович Д., Фридман С.Р., Щербак С.Г.</copyright-holder><copyright-holder xml:lang="en">Sushentseva N.N., Popov O.S., Apalko S.V., Anisenkova A.Y., Azarenko S.V., Smantserev K.V., Khobotnikov D.N., Gladysheva T.V., Minina E.V., Strelyukhina S.V., Urazov S.P., Pavlovich D., Fridman S.R., Shcherbak S.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://cardiovascular.elpub.ru/jour/article/view/2729">https://cardiovascular.elpub.ru/jour/article/view/2729</self-uri><abstract><sec><title>Цель</title><p>Цель. На базе коллекции образцов биобанка СПб ГБУЗ “Городская больница №40” изучить особенности цитокинового профиля у пациентов с септическим поражением на фоне коронавирусной инфекции, вызванной SARS-CoV-2 (Severe Acute Respiratory Syndrome CoronaVirus-2), в сравнении с пациентами с септицемией на фоне абдоминального воспаления.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В исследование были взяты образцы сыворотки крови от 181 пациента с септическим поражением на фоне новой коронавирусной инфекции (127 пациентов с диагнозом, подтвержденным тестированием с помощью полимеразной цепной реакции (ПЦР), и 54 пациента с отрицательным результатом ПЦРанализа, но с характерной картиной компьютерной томографии легких) и 47 пациентов с абдоминальным сепсисом. Содержание цитокинов определяли с помощью мультиплексного иммунофлуоресцентного анализа на базе платформы xMap (Luminex) использованием панели HCYTOMAG-60K — растворимая форма лиганда CD40 (sCD40L), интерлейкин-1α (IL-1α), интерлейкин-1β (IL-1β), интерлейкин 6 (IL-6), интерлейкин 8 (IL-8), моноцитарный хемотаксический белок-1 (MCP-1), фактор некроза опухоли альфа (TNFα), фактор роста эндотелия сосудов (VEGF). Уровни прочих лабораторных показателей (С-реактивный белок (СРБ), ферритин, прокальцитонин) были взяты из историй болезни пациентов. Проверку выборок на нормальность распределения осуществляли методом Шапиро-Уилка. Для сравнения групп использовали критерий Манна-Уитни для несвязанных выборок, критерий Вилкоксона для связанных выборок и метод дисперсионного анализа КраскелаУоллиса с поправкой Бонферрони для множественных сравнений.</p></sec><sec><title>Результаты</title><p>Результаты. У пациентов с септическим поражением на фоне новой коронавирусной инфекции различий в концентрациях цитокинов, ферритина и СРБ между группами с выявленным и не выявленным методом ПЦР SARS-CoV-2 обнаружено не было. На основании этого данная группа при исследовании особенностей цитокинового статуса рассматривалась как гомогенная. При сравнении цитокинового профиля у пациентов с разными типами септического поражения было показано, что в группе пациентов с сепсисом на фоне SARS-CoV-2 наблюдаются значительно более высокие уровни sCD40L (p&lt;0,0001) и VEGF (p=0,037) и относительно низкие СРБ (p&lt;0,0001), IL-6 (p&lt;0,0001), IL-8 (p&lt;0,0001), TNFα (p&lt;0,00058).</p></sec><sec><title>Заключение</title><p>Заключение. Полученные результаты указывают на то, что септическое поражение при COVID-19 протекает с меньшим подъемом уровней воспалительных цитокинов, чем при абдоминальном сепсисе. При этом критически высокий уровень sCD40L указывает на наличие значительного эндотелиального поражения, что полностью вписывается в представления о клинической картине заболевания.</p></sec><sec><title> </title><p> </p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. Using a collection of samples from the biobank ofCityHospital № 40 ofSt. Petersburg, to study the cytokine profile in patients with coronavirus disease 2019 (COVID-19) and sepsis, in comparison with patients with abdominal inflammation and septicemia.</p></sec><sec><title>Material and methods</title><p>Material and methods. The study included serum samples from 181 patients with sepsis and COVID-19 (127 patients with a diagnosis confirmed by polymerase chain reaction (PCR); 54 patients with a negative PCR test, but with a characteristic computed tomographic lung performance) and 47 patients with abdominal sepsis. The content of cytokines was determined using a multiplex immunofluorescence analysis based on the Luminex xMAP technology using the HCYTOMAG60K panel — a soluble CD40 ligand (sCD40L), interleukin-1α (IL-1α), interleukin-1β (IL-1β), interleukin 6 (IL-6), interleukin 8 (IL-8), monocyte chemoattractant protein 1 (MCP-1), tumor necrosis factor alpha (TNFα), vascular endothelial growth factor (VEGF). Other laboratory parameters (C-reactive protein (CRP), ferritin, procalcitonin) were taken from patient records. Normality of distribution was assessed by the Shapiro-Wilk test. To compare groups, the Mann-Whitney test for independent samples, Wilcoxon test for dependent samples, and the Kruskal-Wallis test with Bonferroni correction for multiple comparisons were used.</p></sec><sec><title>Results</title><p>Results. In patients with sepsis and COVID-19 infection, no differences in the concentrations of cytokines, ferritin and CRP were found between the groups with detected and not detected virus by PCR test. Based on this, this group was considered homogeneous when studying the cytokine profile. It was shown that in patients with sepsis and COVID-19, significantly higher levels of sCD40L (p&lt;0,0001) and VEGF (p=0,037) and relatively low levels of CRP (p&lt;0,0001), IL-6 (p&lt;0,0001), IL-8 (p&lt;0,0001), TNFα (p&lt;0,00058).</p></sec><sec><title>Conclusion</title><p>Conclusion. These results indicate that sepsis in patients with COVID-19 courses with less elevation in inflammatory cytokine than in abdominal sepsis. At the same time, a critically high level of sCD40L indicates the significant endothelial damage.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>цитокины</kwd><kwd>COVID-19</kwd><kwd>сепсис</kwd><kwd>биобанк</kwd><kwd>ОРДС</kwd></kwd-group><kwd-group xml:lang="en"><kwd>cytokines</kwd><kwd>COVID-19</kwd><kwd>sepsis</kwd><kwd>biobank</kwd><kwd>acute respiratory distress syndrome</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Wong CK, Lam CW, Wu AK, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004;136(1):95-103. doi: 10.1111/j.1365-2249.2004.02415.x.</mixed-citation><mixed-citation xml:lang="en">Wong CK, Lam CW, Wu AK, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004;136(1):95-103. doi: 10.1111/j.1365-2249.2004.02415.x.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Cheung CY, Poon LL, Ng IH, et al. Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis. J Virol. 2005;79(12):7819-26. doi: 10.1128/JVI.79.12.7819-7826.2005.</mixed-citation><mixed-citation xml:lang="en">Cheung CY, Poon LL, Ng IH, et al. Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis. J Virol. 2005;79(12):7819-26. doi: 10.1128/JVI.79.12.7819-7826.2005.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Cross LM, Matthay MA. Biomarkers in acute lung injury: insights into the pathogenesis of acute lung injury. Critical care clinics. 2011;27(2):355-377. doi: 10.21037/atm.2018.01.10.</mixed-citation><mixed-citation xml:lang="en">Cross LM, Matthay MA. Biomarkers in acute lung injury: insights into the pathogenesis of acute lung injury. Critical care clinics. 2011;27(2):355-377. doi: 10.21037/atm.2018.01.10.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Roncati L, Ligabue G, Fabbiani L, et al. Type 3 hypersensitivity in COVID-19 vasculitis. Clin Immunol. 2020;217:108487. doi: 10.1016/j.clim.2020.108487.</mixed-citation><mixed-citation xml:lang="en">Roncati L, Ligabue G, Fabbiani L, et al. Type 3 hypersensitivity in COVID-19 vasculitis. Clin Immunol. 2020;217:108487. doi: 10.1016/j.clim.2020.108487.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Vijayan AL, Ravindran S, Saikant R, Lakshmi S, et al. Procalcitonin: a promising diagnostic marker for sepsis and antibiotic therapy. Journal of intensive care. 2017;5(1):1-7. doi: 10.1186/s40560-017-0246-8.</mixed-citation><mixed-citation xml:lang="en">Vijayan AL, Ravindran S, Saikant R, Lakshmi S, et al. Procalcitonin: a promising diagnostic marker for sepsis and antibiotic therapy. Journal of intensive care. 2017;5(1):1-7. doi: 10.1186/s40560-017-0246-8.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Povoa P, Coelho L, Almeida E, et al. C-reactive protein as a marker of infection in critically ill patients. Clinical microbiology and infection. 2005;11(2):101-108. doi: 10.1111/j.1469-0691.2004.01044.x.</mixed-citation><mixed-citation xml:lang="en">Povoa P, Coelho L, Almeida E, et al. C-reactive protein as a marker of infection in critically ill patients. Clinical microbiology and infection. 2005;11(2):101-108. doi: 10.1111/j.1469-0691.2004.01044.x.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Russo RC, Garcia CC, Teixeira MM, et al. The CXCL8/IL-8 chemokine family and its receptors in inflammatory diseases. Expert Rev Clin Immunol. 2014;10(5):593-619. doi: 10.1586/1744666X.2014.894886.</mixed-citation><mixed-citation xml:lang="en">Russo RC, Garcia CC, Teixeira MM, et al. The CXCL8/IL-8 chemokine family and its receptors in inflammatory diseases. Expert Rev Clin Immunol. 2014;10(5):593-619. doi: 10.1586/1744666X.2014.894886.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Dahlgren C, Karlsson A, Bylund J. Intracellular Neutrophil Oxidants: From Laboratory Curiosity to Clinical Reality. J Immunol. 2019;202(11):3127-3134. doi: 10.4049/jimmunol.1900235.</mixed-citation><mixed-citation xml:lang="en">Dahlgren C, Karlsson A, Bylund J. Intracellular Neutrophil Oxidants: From Laboratory Curiosity to Clinical Reality. J Immunol. 2019;202(11):3127-3134. doi: 10.4049/jimmunol.1900235.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">De Biasi S, Meschiari M, Gibellini L., et al. Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia. Nature communications. 2020;11(1):1-17. doi: 10.1038/s41467-020-17292-4.</mixed-citation><mixed-citation xml:lang="en">De Biasi S, Meschiari M, Gibellini L., et al. Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia. Nature communications. 2020;11(1):1-17. doi: 10.1038/s41467-020-17292-4.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Ijaz T, Sun H, Pinchuk IV, et al. Deletion of NF-kappaB/RelA in angiotensin II‐sensitive mesenchymal cells blocks aortic vascular inflammation and abdominal aortic aneurysm formation. Arterioscler Thromb Vasc Biol. 2017;37(10):188-1890. doi: 10.1161/JAHA.113.000476.</mixed-citation><mixed-citation xml:lang="en">Ijaz T, Sun H, Pinchuk IV, et al. Deletion of NF-kappaB/RelA in angiotensin II‐sensitive mesenchymal cells blocks aortic vascular inflammation and abdominal aortic aneurysm formation. Arterioscler Thromb Vasc Biol. 2017;37(10):188-1890. doi: 10.1161/JAHA.113.000476.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Roncati L, Nasillo V, Lusenti B, et al. Signals of Th2 immune response from COVID‐19 patients requiring intensive care. Ann Hematol. 2020; 99(6):1419-1420. doi: 10.1007/s00277-020-04066-7.</mixed-citation><mixed-citation xml:lang="en">Roncati L, Nasillo V, Lusenti B, et al. Signals of Th2 immune response from COVID‐19 patients requiring intensive care. Ann Hematol. 2020; 99(6):1419-1420. doi: 10.1007/s00277-020-04066-7.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang C, Wu Z, Li JW, et al. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents. 2020;55(5):105954. doi: 10.1016/j.ijantimicag.2020.105954.</mixed-citation><mixed-citation xml:lang="en">Zhang C, Wu Z, Li JW, et al. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents. 2020;55(5):105954. doi: 10.1016/j.ijantimicag.2020.105954.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Blondonnet R, Constantin JM, Sapin V, et al. A pathophysiologic approach to biomarkers in acute respiratory distress syndrome. Dis Markers. 2016;2016:3501373. doi:10.1155/2016/3501373</mixed-citation><mixed-citation xml:lang="en">Blondonnet R, Constantin JM, Sapin V, et al. A pathophysiologic approach to biomarkers in acute respiratory distress syndrome. Dis Markers. 2016;2016:3501373. doi:10.1155/2016/3501373</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Lorente L, Martín MM, Pérez-Cejas A, et al. Non-survivor septic patients have persistently higher serum sCD40L levels than survivors. Journal of Critical Care. 2017;41:177-182. doi: org/10.1016/j.jcrc.2017.05.021.</mixed-citation><mixed-citation xml:lang="en">Lorente L, Martín MM, Pérez-Cejas A, et al. Non-survivor septic patients have persistently higher serum sCD40L levels than survivors. Journal of Critical Care. 2017;41:177-182. doi: org/10.1016/j.jcrc.2017.05.021.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
